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LB-ARHGDIB-1R as a novel minor histocompatibility
antigen for therapeutic application
In HLA-matched allogeneic hematopoietic stem cell
transplantation (SCT), donor T cells can mediate 
graft-versus-leukemia/lymphoma (GvL) reactivity and
graft-versus-host disease (GvHD) by recognition of minor
histocompatibility antigens (MiHA).1-4 Only a minority of
MiHA shows hematopoiesis-restricted expression, and
donor T cells for these MiHA may induce beneficial GvL
reactivity without GvHD. The number of well-character-
ized MiHA with therapeutic relevance based on
hematopoiesis-restricted expression remains limited and
only 25% and 40% of recipients transplanted with grafts
from sibling and unrelated donors, respectively, are eligi-
ble for therapies targeting known hematopoietic MiHA.3,4
Thus, in order to increase the efficacy and applicability of
cellular therapy for selective GvL induction, more
hematopoiesis-restricted MiHA with balanced popula-
tion frequencies in common HLA molecules must be
identified. Here, we investigated the therapeutic signifi-
cance of a MiHA encoded by ARHGDIB.5 We demon-
strated hematopoiesis-restricted gene expression with
the exception of intermediate mRNA expression in
endothelial cells and showed that T cells recognized 
LB-ARHGDIB-1R presented by HLA-B*07:02 on primary
leukemic cells, but not on [interferon-gamma (IFN-γ)]-
treated fibroblasts and keratinocytes. To evaluate poten-
tial toxicity against endothelial cells, we tested T cell
recognition of LB-ARHGDIB-1R on human umbilical vein
endothelial cells (HUVEC) and found only limited reac-
tivity under inflammatory conditions. Furthermore, we
demonstrated in vivo targeting of LB-ARHGDIB-1R in
eight out of ten patients who were screened for post-
transplant specific T-cell responses. In one patient with
relapsed lymphoma, high T-cell frequencies were induced
after donor lymphocyte infusion (DLI), coinciding with
long-lasting anti-lymphoma immunity without GvHD.
Our data thus support the relevance of LB-ARHGDIB-1R
as a therapeutic target with the potential to induce selec-
tive GvL reactivity. 
We previously demonstrated that CD8 T cells specific
for a MiHA (LB-ARHGDIB-1R) encoded by the
ARHGDIB gene were induced in a patient with
myelodysplastic syndrome who responded to DLI after
HLA-matched allogeneic SCT.5 LB-ARHGDIB-1R is trans-
lated from the normal ARHGDIB transcript (NM_001175)
in an alternative reading frame. Since ARHGDIB has been
described to be expressed in hematopoietic cells,6,7 we
investigated the therapeutic value of LB-ARHGDIB-1R to
stimulate GvL reactivity after allogeneic SCT without
GvHD. We first examined ARHGDIB expression by
microarray gene expression analysis using Illumina HT-
12 v3/4 BeadChips8 and compared gene expression
between (malignant) hematopoietic and non-hematopoi-
etic cells, which were cultured in the absence or presence
of IFN-γ to mimic a state of inflammation. ARHGDIB
showed strong overexpression in the majority of (malig-
nant) hematopoietic versus (IFN-γ pre-treated) non-
hematopoietic cells. The ARHGDIB expression profile
was comparable to the strictly hematopoietic HMHA1
and MYO1G (Figure 1A and data not shown). 
Next, we investigated T-cell recognition of different
leukemic samples and both primary fibroblasts and ker-
atinocytes cultured from skin biopsies in the absence or
presence of IFN-γ. Samples were collected from patients
and healthy individuals after approval from the Leiden or
Radboud UMC Institutional Review Board and informed
consent according to the Declaration of Helsinki.
Recognition of (non-)hematopoietic cell types by 
LB-ARHGDIB-1R-specific T cells was measured by 
IFN-γ enzyme-linked immunosorbent assay (ELISA) after
overnight co-incubation. The data confirmed
hematopoiesis-restricted T-cell recognition of LB-
ARHGDIB-1R in HLA-B*07:02 on all MiHA-positive
leukemic cells, but not on (IFN-γ pre-treated) fibroblasts
and keratinocytes (Figure 1B). T cells for LB-ARHGDIB-
1R were also shown to recognize healthy hematopoietic
cell types, including Epstein-Barr virus-infected  (EBV) 
B cells, phytohemagglutinin-stimulated T cells and den-
dritic cells (Figure 1B and data not shown), indicating that
alternative translation of LB-ARHGDIB-1R is not restrict-
ed to malignant cells. T cells for LB-ARHGDIB-1R also
showed specific lysis of patient’s, but not donor’s, 
EBV-B cells and specific lysis of an acute lymphoblastic
leukemia sample (ALL #1) in a 10 h 51Cr-release assay
(Figure 1C). Lysis of other acute lymphoblastic and
myeloid leukemia samples was not detected by 51Cr-
release, but could be measured after 48 h co-incubation
in a flow cytometry-based cytotoxicity assay, while (IFN-
γ pre-treated) patient’s fibroblasts were not lysed (Figure
1D and data not shown). The data showed that T cells for
LB-ARHGDIB-1R can specifically lyse hematological
malignancies of different origins. 
In addition to hematopoietic cells, ARHGDIB can also
be expressed in endothelial cells.9 Therefore, we
addressed potential toxicity and measured T-cell reactivi-
ty against endothelial cells. We confirmed intermediate
ARHGDIB gene expression in HUVEC under both steady-
state and inflammatory conditions by microarray gene
expression analysis (Online Supplementary Figure S1A,
upper panel). Increased ARHGDIB mRNA expression in
HUVEC as compared to fibroblasts was also detectable
by quantitative polymerase chain reaction analysis (see
Online Supplementary Methods) (Online Supplementary
Figure S1A, lower panel). To investigate whether gene
expression in HUVEC can lead to T-cell recognition, we
measured reactivity against two LB-ARHGDIB-1R-posi-
tive HUVEC samples by IFN-γ ELISA. T cells for LB-
ARHGDIB-1R were only capable of recognizing one
HUVEC sample (#2) after IFN-γ pre-treatment, which is
known to up-regulate HLA, co-stimulatory and adhesion
molecules and to increase the antigen processing and
presentation capacity (Online Supplementary Figure
S1B).10,11 However, recognition of HUVEC #2 was low
compared to EBV-B cells and (IFN-γ pre-treated) HUVEC
#1 was not or hardly recognized by specific T cells.
Altogether, we demonstrate that ARGHDIB gene expres-
sion in HUVEC leads to low surface presentation of 
LB-ARHGDIB-1R that triggers only minimal T-cell reac-
tivity under inflammatory conditions. Our results thus
support the value of LB-ARHGDIB-1R as a target for 
T-cell therapy to selectively augment GvL reactivity after
allogeneic SCT with a limited risk of GvHD. 
Finally, we determined the in vivo immunogenicity of
LB-ARHGDIB-1R and investigated its relevance as a 
T-cell target in clinical responses after allogeneic SCT.
The population frequency of LB-ARHGDIB-1R in
Caucasians is 77% (www.hapmap.org), resulting in a dis-
parity rate, in which a LB-ARHGDIB-1R-positive patient
is transplanted with a negative donor, of 18%. HLA-
B*07:02 is expressed in approximately 20% of
Caucasians.12 In our cohort of 93 HLA-B*07:02 patient-
donor pairs, 14 LB-ARHGDIB-1R-positive patients were
transplanted with a MiHA-negative donor and samples at
relevant time points were available for ten patients.
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Peripheral blood mononuclear cells were stained with
APC- and PE-conjugated HLA-B*07:02 tetramers contain-
ing LB-ARHGDIB-1R directly ex vivo as well as after 7
days of in vitro peptide stimulation as previously
described.13 Peripheral blood mononuclear cells obtained
after allogeneic SCT (and DLI) were analyzed for
tetramer-positive T cells, and LB-ARHGDIB-1R-specific T
cells were detected in four patients ex vivo (Figure 2A) and
in four additional patients after in vitro peptide stimula-
tion (Figure 2B), resulting in eight positive patients (80%)
out of a total of ten. 
All patients were treated with partial T-cell-depleted
allogeneic SCT followed by at least 4 months of immuno-
suppression with cyclosporine A as GvHD prophylaxis.
Six of ten patients received DLI after allogeneic SCT
(Online Supplementary Table S1). In three of six patients
treated with DLI, tetramer-positive T cells were detected
ex vivo at frequencies between 0.06-0.92%. Five patients
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(C) Cytolysis of primary leukemic blasts as mediated by T cells for LB-ARHGDIB-1R in a 51Cr-release assay. Target cells (1x103) labeled with
Na251CrO4 (Perkin Elmer, Waltham, MA, USA) were co-incubated with T cells for 10 hours (h) at effector:target ratios of 10:1, 3:1 and 1:1.
Mean specific lysis of triplicate wells is shown for patient and donor EBV-B (upper and middle graphs, respectively) and ALL #1 expressing
LB-ARHGDIB-1R and HLA-B*07:02 (lower graph). Patient and donor EBV-B and ALL #1 were positive for HLA-A*02:01 and negative for
LB-GEMIN4-1V. Allo-HLA-A*02:01 reactive T cells (clone HSS12) and T cells for LB-GEMIN4-1V were included as controls. (D) Cytolysis of
primary leukemic blasts and patient’s FB as mediated by T cells for LB-ARHGDIB-1R in a 48 h flow cytometry-based cytotoxicity assay. 
T cells (2.5x104) were labeled with PKH67 (Sigma-Aldrich, St. Louis, MO, USA) and co-incubated for 48 h with AML or ALL samples or FB
cultured from a skin biopsy of the patient in the absence or presence of IFN-γ (1x104). After co-incubation, cultures were stained with
CD33-APC (AML), CD19-PE (ALL) or CD90-PE (FB). Sytox blue was added to gate on viable cells and flow count fluorospheres (Beckman
Coulter, Brea, CA, USA) were added to calculate specific lysis. T cells recognizing HA-2 in HLA-A*02:01 (clone 9H11), T cells for LB-
GEMIN4-1V and Allo-HLA-A*02:01 reactive T cells were included as controls. Mean lysis of triplicate wells is depicted.
Figure 1. LB-ARHGDIB-1R as a target
with therapeutic relevance for leukemia.
(A) Expression profiles for ARHGDIB and
GEMIN4 as determined by microarray
gene expression analysis. GEMIN4 was
selected as a representative gene for
MiHA with ubiquitous expression on 
(non)-La by (non-)hematopoietic cells.5
The probe fluorescence, as measured on
Illumina Human HT-12 v3/4 BeadChips,
is indicated.8 Hematopoietic cells includ-
ed bone marrow and peripheral blood
mononuclear cells (BMMC and PBMC), 
B cells, T cells, monocytes (Mono),
macrophages type I and II (MØ1 and
MØ2), (im)mature DC (imDC and matDC),
hematopoietic stem cells (HSC), Epstein-
Barr virus-infected B (EBV-B) cells and
phytohemagglutinin-stimulated T (PHA-T)
cells. Malignant hematopoietic cells
included acute lymphoblastic leukemia
(ALL), acute myeloid leukemia (AML),
chronic myeloid leukemia (CML), chronic
lymphocytic leukemia (CLL) and multiple
myeloma (MM). Non-hematopoietic cells
included fibroblasts (FB) and ker-
atinocytes (KC) cultured from skin biop-
sies in the absence or presence of IFN-γ
and hepatocytes, colon and small intes-
tine epithelial cells and lung epithelial
cells.  (B-D) Recognition and lysis of 
(non-)hematopoietic cells as mediated by 
T cells for LB-ARHGDIB-1R (clone H10).5
All samples were positive for HLA-
B*07:02. Cell types included EBV-B and
PHA-T cells from patient (PAT EBV #1 and
PHA #1) or donor (DON EBV #2) origin or
from third party individuals (EBV #3, EBV
#4 and PHA #3) as well as primary ALL
(ALL #1-3) and AML (AML #1-3) samples.
One representative example of two inde-
pendent experiments is shown.  (B)
Recognition of LB-ARHGDIB-1R in HLA-
B*07:02 as expressed on (malignant)
hematopoietic cells, but not on (IFN-γ
pre-treated) FB and KC. Malignant cells
were isolated by flow cytometry cell sort-
ing based on CD19 (ALL) or CD33 (AML)
expression. T cells for LB-GEMIN4-1V
(clone Z1)  were included as a positive
control. Genotyping results (+ or -) for the
single nucleotide polymorphisms encod-
ing LB-ARHGDIB-1R (filled bars) and LB-
GEMIN4-1V (open bars) are shown. Mean
release of IFN-γ of duplicate wells as
measured by ELISA after overnight 
co-incubation of T cells and stimulator
cells at a ratio of 1:6 is depicted.  
A B
C D
received prophylactic DLI, and a clinical response against
(malignant) hematopoietic cells of patient origin could
not therefore be monitored. Patient #5 with relapsed fol-
licular lymphoma, which was confirmed by lymph node
biopsy, received therapeutic DLI that in the absence of
additional (chemo)therapy induced a long-lasting com-
plete remission (>16 years) without any signs of GvHD.
T cells for LB-ARHGDIB-1R were measured in three
patients with GvHD after DLI (patients #2, 6 and 7).
These T cells were detectable 
ex vivo (0.92%) in patient #2 and after in vitro stimulation
in the other two patients. Although it cannot be excluded
that T cells for LB-ARHGDIB-1R may have contributed
to GvHD in these patients, we consider it more likely
that T cells with other specificities mediated GvHD, since
we previously demonstrated that a variety of MiHA are
often targeted in patients with GvHD5,14 and that the
majority of these MiHA are ubiquitously expressed on
(non-)hematopoietic tissues. This is further supported by
the observation that T cells for LB-ARHGDIB-1R were
also measured ex vivo (0.13%) in patient #5. Induction of
tetramer-positive T cells in this patient 2 months after
DLI coincided with long-lasting GvL reactivity without
GvHD. Dynamic analysis of LB-ARHGDIB-1R tetramer-
positive T cells in this patient demonstrated high fre-
quencies not only after DLI, but also within the first
weeks after allogeneic SCT during immunosuppression
with cyclosporine A (Figure 2C). Although the long-last-
ing GvL response in patient #5 suggests that LB-
ARHGDIB-1R-specific T cells are capable of mediating
strong anti-tumor immunity, T cells with specificities
other than LB-ARHGDIB-1R may also be involved in the
therapeutic effect of DLI. Systemic toxicity as a result of
vascular damage has not been observed in any of the
patients with circulating LB-ARHGDIB-1R-specific 
T cells. Thus, clinical observations support the therapeu-
tic value of LB-ARHGDIB-1R and do not show evidence
for specific attack of endothelial cells as might be suggest-
ed based on detectable ARHGDIB gene expression and
low T-cell recognition of endothelial cells in vitro. 
In conclusion, our data support the relevance of LB-
ARHGDIB-1R as highly immunogenic and
hematopoiesis-restricted MiHA with the potential to
shift the delicate balance between GvL reactivity and
GvHD in favor of desired anti-tumor reactivity. At the
Radboud UMC, we have started a clinical trial in which
transplanted patients are vaccinated with donor dendritic
cells loaded with mRNA and included ARHGDIB as one
of the transcripts for hematopoiesis-restricted MiHA
(Dutch Trial Registry #NTR4128). Future clinical data
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Figure 2. LB-ARHGDIB-1R as an
immunogenic target with rele-
vance for GvL reactivity. Peripheral
blood mononuclear cells from ten
LB-ARHGDIB-1R and HLA-B*07:02
positive patients transplanted with
HLA-matched negative donors
were screened for LB-ARHGDIB-1R-
specific CD8 T cells directly ex vivo
as well as after 1 week of in vitro
peptide stimulation (IVS).13 (A)
Patients with detectable LB-
ARHGDIB-1R tetramer-positive 
T-cells ex vivo. Numbers indicate
the percentage of CD8 T cells that
are positive for both LB-ARHGDIB-
1R tetramers (PE and APC) in the
Sytox blueneg, CD8pos, CD4neg,
CD14neg, CD16neg, and CD19neg
T-cell population. (B) Dot plots of
patients with detectable 
LB-ARHGDIB-1R tetramer-positive 
T cells after IVS: day 0 (upper pan-
els) and day 7 (lower panels).
Numbers indicate the percentage
of CD8 T cells that are positive for
both LB-ARHGDIB-1R tetramers
(PE and APC).  (C) Ex vivo frequen-
cies of LB-ARHGDIB-1R specific T
cells and clinical response in
patient #5 who was treated with
DLI in the absence of additional
(chemo) therapy for relapsed lym-
phoma after partial 
T-cell-depleted allogeneic SCT.   
A
B
C
Weeks after allogeneic SCT
will, therefore, provide definite evidence of whether T
cells for LB-ARHGDIB-1R are capable of inducing selec-
tive GvL responses. In addition to hematopoietic cells,
ARHGDIB has been reported to be expressed in several
solid tumors correlating with advanced tumor stage and
metastatic potential.15 As such, LB-ARHGDIB-1R may
have broad value as a target for T-cell therapy to treat
hematologic malignancies and solid tumors after allo-
geneic SCT.
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